Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation.
Napolitano S, Martini G, Martinelli E, Belli V, Parascandolo A, Laukkanen MO, Sforza V, Morgillo F, Ciardiello D, Ciardiello F, Troiani T. Napolitano S, et al. Among authors: sforza v. Oncotarget. 2017 Jun 27;8(40):67592-67604. doi: 10.18632/oncotarget.18749. eCollection 2017 Sep 15. Oncotarget. 2017. PMID: 28978055 Free PMC article.
Risk Management Activities in a Lung Cancer Multidisciplinary Team at a Comprehensive Cancer Center: Results of a Prospective Analysis.
Morabito A, Mercadante E, Muto P, Palumbo G, Manzo A, Montanino A, Sandomenico C, Sforza V, Costanzo R, Damiano S, La Manna C, Martucci N, La Rocca A, De Luca G, Totaro G, De Cecio R, Picone C, Piccirillo MC, De Feo G, Tracey M, D'Auria S, Normanno N, Capasso A, Pascarella G. Morabito A, et al. Among authors: sforza v. JCO Oncol Pract. 2023 Mar;19(3):e315-e325. doi: 10.1200/OP.22.00358. Epub 2022 Nov 16. JCO Oncol Pract. 2023. PMID: 36383923
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F. Martinelli E, et al. Among authors: sforza v. Int J Cancer. 2013 Nov;133(9):2089-101. doi: 10.1002/ijc.28236. Epub 2013 May 29. Int J Cancer. 2013. PMID: 23629727
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, Bianco R, Ciardiello F. Troiani T, et al. Among authors: sforza v. Clin Cancer Res. 2013 Dec 15;19(24):6751-65. doi: 10.1158/1078-0432.CCR-13-0423. Epub 2013 Oct 11. Clin Cancer Res. 2013. PMID: 24122793
Treatment of gastric cancer.
Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E, Ciardiello F, De Vita F. Orditura M, et al. Among authors: sforza v. World J Gastroenterol. 2014 Feb 21;20(7):1635-49. doi: 10.3748/wjg.v20.i7.1635. World J Gastroenterol. 2014. PMID: 24587643 Free PMC article. Review.
Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Troiani T, Napolitano S, Vitagliano D, Morgillo F, Capasso A, Sforza V, Nappi A, Ciardiello D, Ciardiello F, Martinelli E. Troiani T, et al. Among authors: sforza v. Clin Cancer Res. 2014 Jul 15;20(14):3775-86. doi: 10.1158/1078-0432.CCR-13-2181. Epub 2014 May 8. Clin Cancer Res. 2014. PMID: 24812410
100 results